S-adenosylhomocysteine is associated with subclinical atherosclerosis and renal function in a cardiovascular low-risk population

Atherosclerosis

Volumn 234, Issue 1, 2014, Pages 17-22

  Zawada, Adam M ^a   Rogacev, Kyrill S ^a   Hummel, Björn ^a,c   Berg, Judith T ^a   Friedrich, Annika ^a   Roth, Heinz J ^b   Obeid, Rima ^a   Geisel, Jürgen ^a   Fliser, Danilo ^a   Heine, Gunnar H ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b Labor Dr Limbach und Kollegen   (Germany)

^c Department of Clinical Hemostaseology and Transfusion Medicine ^*  (Germany)

Author keywords

Arteriosclerosis; Homocysteine; Kidney; S adenosylhomocysteine; S adenosylmethionine

Indexed keywords

HOMOCYSTEINE; S ADENOSYLHOMOCYSTEINE; S ADENOSYLMETHIONINE;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; METABOLISM; PRIORITY JOURNAL; SUBCLINICAL ATHEROSCLEROSIS; ASYMPTOMATIC DISEASE; CARDIOVASCULAR DISEASES; COMPLICATION; MIDDLE AGED; PATHOPHYSIOLOGY; RISK FACTOR;

ASYMPTOMATIC DISEASES; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; FEMALE; GLOMERULAR FILTRATION RATE; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; S-ADENOSYLHOMOCYSTEINE; S-ADENOSYLMETHIONINE;

EID: 84897991350     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.02.002     Document Type: Article

References (44)

1. Anderson J.L., Muhlestein J.B., Horne B.D., et al. Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. Circulation 2000, 102:1227-1232.
2. Mallamaci F., Zoccali C., Tripepi G., et al. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int 2002, 61:609-614.
3. Nygard O., Nordrehaug J.E., Refsum H., Ueland P.M., Farstad M., Vollset S.E. Plasma homocysteine levels and mortality in patients with coronary artery disease. NEngl J Med 1997, 337:230-236.
4. Veeranna V., Zalawadiya S.K., Niraj A., et al. Homocysteine and reclassification of cardiovascular disease risk. JAm Coll Cardiol 2011, 58:1025-1033.
5. Heinz J., Kropf S., Domrose U., et al. Bvitamins and the risk of total mortality and cardiovascular disease in end-stage renal disease: results of a randomized controlled trial. Circulation 2010, 121:1432-1438.
6. Jamison R.L., Hartigan P., Kaufman J.S., et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 2007, 298:1163-1170.
7. Lonn E., Yusuf S., Arnold M.J., et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. NEngl J Med 2006, 354:1567-1577.
8. Zoungas S., McGrath B.P., Branley P., et al. Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial. JAm Coll Cardiol 2006, 47:1108-1116.
9. Wagner C., Koury M.J. S-Adenosylhomocysteine: a better indicator of vascular disease than homocysteine?. Am J Clin Nutr 2007, 86:1581-1585.
10. Zawada A.M., Rogacev K.S., Heine G.H. Clinical relevance of epigenetic dysregulation in chronic kidney disease-associated cardiovascular disease. Nephrol Dial Transplant 2013, 28:1663-1671.
11. Hubner U., Geisel J., Kirsch S.H., et al. Effect of 1 year B and D vitamin supplementation on LINE-1 repetitive element methylation in older subjects. Clin Chem Lab Med 2013, 51:649-655.
12. Green T.J., Skeaff C.M., McMahon J.A., et al. Homocysteine-lowering vitamins do not lower plasma S-adenosylhomocysteine in older people with elevated homocysteine concentrations. Br J Nutr 2010, 103:1629-1634.
13. Kerins D.M., Koury M.J., Capdevila A., Rana S., Wagner C. Plasma S-adenosylhomocysteine is a more sensitive indicator of cardiovascular disease than plasma homocysteine. Am J Clin Nutr 2001, 74:723-729.
14. Liu C., Wang Q., Guo H., et al. Plasma S-adenosylhomocysteine is a better biomarker of atherosclerosis than homocysteine in apolipoprotein E-deficient mice fed high dietary methionine. JNutr 2008, 138:311-315.
15. Xiao Y., Zhang Y., Wang M., et al. Plasma S-adenosylhomocysteine is associated with the risk of cardiovascular events in patients undergoing coronary angiography: a cohort study. Am J Clin Nutr 2013, 98:1162-1169.
16. Garibotto G., Valli A., Anderstam B., et al. The kidney is the major site of S-adenosylhomocysteine disposal in humans. Kidney Int 2009, 76:293-296.
17. Jabs K., Koury M.J., Dupont W.D., Wagner C. Relationship between plasma S-adenosylhomocysteine concentration and glomerular filtration rate in children. Metabolism 2006, 55:252-257.
18. Zawada A.M., Rogacev K.S., Hummel B., et al. SuperTAG methylation-specific digital karyotyping reveals uremia-induced epigenetic dysregulation of atherosclerosis-related genes. Circ Cardiovasc Genet 2012, 5:611-620.
19. Rogacev K.S., Ulrich C., Blomer L., et al. Monocyte heterogeneity in obesity and subclinical atherosclerosis. Eur Heart J 2010, 31:369-376.
20. Inker L.A., Schmid C.H., Tighiouart H., et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. NEngl J Med 2012, 367:20-29.
21. Kirsch S.H., Knapp J.P., Geisel J., Herrmann W., Obeid R. Simultaneous quantification of S-adenosyl methionine and S-adenosyl homocysteine in human plasma by stable-isotope dilution ultra performance liquid chromatography tandem mass spectrometry. JChromatogr B Analyt Technol Biomed Life Sci 2009, 877:3865-3870.
22. Au-Yeung K.K., Woo C.W., Sung F.L., et al. Hyperhomocysteinemia activates nuclear factor-kappaB in endothelial cells via oxidative stress. Circ Res 2004, 94:28-36.
23. Majors A., Ehrhart L.A., Pezacka E.H. Homocysteine as a risk factor for vascular disease. Enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol 1997, 17:2074-2081.
24. Poddar R., Sivasubramanian N., DiBello P.M., Robinson K., Jacobsen D.W. Homocysteine induces expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human aortic endothelial cells: implications for vascular disease. Circulation 2001, 103:2717-2723.
25. Bienvenu T., Ankri A., Chadefaux B., Montalescot G., Kamoun P. Elevated total plasma homocysteine, a risk factor for thrombosis. Relation to coagulation and fibrinolytic parameters. Thromb Res 1993, 70:123-129.
26. Perna A.F., Ingrosso D., Violetti E., et al. Hyperhomocysteinemia in uremia-a red flag in a disrupted circuit. Semin Dial 2009, 22:351-356.
27. Loehrer F.M., Angst C.P., Brunner F.P., Haefeli W.E., Fowler B. Evidence for disturbed S-adenosylmethionine: S-adenosylhomocysteine ratio in patients with end-stage renal failure: a cause for disturbed methylation reactions?. Nephrol Dial Transplant 1998, 13:656-661.
28. Perna A.F., Ingrosso D., Zappia V., Galletti P., Capasso G., De Santo N.G. Enzymatic methyl esterification of erythrocyte membrane proteins is impaired in chronic renal failure. Evidence for high levels of the natural inhibitor S-adenosylhomocysteine. JClin Invest 1993, 91:2497-2503.
29. Luo X., Xiao Y., Song F., Yang Y., Xia M., Ling W. Increased plasma S-adenosyl-homocysteine levels induce the proliferation and migration of VSMCs through an oxidative stress-ERK1/2 pathway in apoE(-/-) mice. Cardiovasc Res 2012, 95:241-250.
30. Sipkens J.A., Hahn N.E., Blom H.J., et al. S-Adenosylhomocysteine induces apoptosis and phosphatidylserine exposure in endothelial cells independent of homocysteine. Atherosclerosis 2012, 221:48-54.
31. Baccarelli A., Wright R., Bollati V., et al. Ischemic heart disease and stroke in relation to blood DNA methylation. Epidemiology 2010, 21:819-828.
32. Castillo-Diaz S.A., Garay-Sevilla M.E., Hernandez-Gonzalez M.A., Solis-Martinez M.O., Zaina S. Extensive demethylation of normally hypermethylated CpG islands occurs in human atherosclerotic arteries. Int J Mol Med 2010, 26:691-700.
33. Hiltunen M.O., Turunen M.P., Hakkinen T.P., et al. DNA hypomethylation and methyltransferase expression in atherosclerotic lesions. Vasc Med 2002, 7:5-11.
34. Turunen M.P., Aavik E., Yla-Herttuala S. Epigenetics and atherosclerosis. Biochim Biophys Acta 2009, 1790:886-891.
35. Zawadzki C., Chatelain N., Delestre M., et al. Tissue factor pathway inhibitor-2 gene methylation is associated with low expression in carotid atherosclerotic plaques. Atherosclerosis 2009, 204:e4-14.
36. Ingrosso D., Cimmino A., Perna A.F., et al. Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia. Lancet 2003, 361:1693-1699.
37. Zawada A.M., Rogacev K.S., Muller S., et al. Massive Analysis of cDNA Ends (MACE) and miRNA expression profiling identifies proatherogenic pathways in chronic kidney disease MACE and miRNA profiling in CKD. Epigenetics 2014, 9:161-172.
38. Castro R., Rivera I., Struys E.A., et al. Increased homocysteine and S-adenosylhomocysteine concentrations and DNA hypomethylation in vascular disease. Clin Chem 2003, 49:1292-1296.
39. Valli A., Carrero J.J., Qureshi A.R., et al. Elevated serum levels of S-adenosylhomocysteine, but not homocysteine, are associated with cardiovascular disease in stage 5 chronic kidney disease patients. Clin Chim Acta 2008, 395:106-110.
40. Boushey C.J., Beresford S.A., Omenn G.S., Motulsky A.G. Aquantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995, 274:1049-1057.
41. Durga J., Verhoef P., Bots M.L., Schouten E. Homocysteine and carotid intima-media thickness: a critical appraisal of the evidence. Atherosclerosis 2004, 176:1-19.
42. Boger R.H., Bode-Boger S.M., Sydow K., Heistad D.D., Lentz S.R. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000, 20:1557-1564.
43. Meinitzer A., Kielstein J.T., Pilz S., et al. Symmetrical and asymmetrical dimethylarginine as predictors for mortality in patients referred for coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study. Clin Chem 2011, 57:112-121.
44. Hsu C.Y., Propert K., Xie D., et al. Measured GFR does not outperform estimated GFR in predicting CKD-related complications. JAm Soc Nephrol 2011, 22:1931-1937.